Type 2 diabetes occurs when your body cannot use insulin effectively or produce enough insulin to maintain blood glucose within normal ranges of 4.0-5.9 mmol/L (fasting) or below 7.8 mmol/L (2 hours after meals). Unlike type 1 diabetes, where the pancreas produces no insulin, type 2 diabetes involves insulin resistance, where cells respond poorly to insulin, combined with decreased insulin production over time.
Treatment aims to achieve HbA1c levels below 7.0% for most adults, though targets may vary based on age, duration of diabetes, and other medical conditions. The approach combines lifestyle modifications with medications, adjusting treatment intensity based on individual response and disease progression.
Lifestyle Modifications as Foundation Treatment
Dietary changes form the cornerstone of type 2 diabetes management. Carbohydrate counting helps predict blood glucose response, with 15 grams of carbohydrates typically raising blood glucose by 2-3 mmol/L. Focus on complex carbohydrates with a glycemic index below 55, including whole grains, legumes, and non-starchy vegetables.
Portion control using the plate method allocates half your plate to non-starchy vegetables, one quarter to lean protein, and one quarter to whole grains or starchy vegetables. This visual guide eliminates calorie counting while naturally limiting carbohydrate intake to 45-60 grams per meal.
Physical activity improves insulin sensitivity for up to 48 hours after exercise. Aim for 150 minutes of moderate-intensity aerobic activity per week, distributed across at least 3 days. Resistance training twice weekly further enhances glucose uptake by increasing muscle mass, the primary site of glucose disposal.
Weight reduction of 5-10% body weight significantly improves glycemic control. Each kilogram lost typically reduces HbA1c by 0.1%. Sustainable weight loss occurs through creating a daily caloric deficit of 500-750 calories, combining dietary changes with increased physical activity.
Oral Medications for Blood Glucose Control
Metformin remains the first-line medication, reducing hepatic glucose production and improving insulin sensitivity. The starting dose typically begins at 500mg once or twice daily with meals, gradually increasing to a maximum dose of 2000-2550mg daily based on tolerance and glycemic response.
Common side effects of metformin include gastrointestinal discomfort. Extended-release formulations reduce these effects. Vitamin B12 levels require annual monitoring, as long-term metformin use may cause deficiency.
Sulfonylureas such as glipizide and gliclazide stimulate pancreatic beta-cell insulin secretion. These medications act quickly but carry risks, particularly when meal timing is irregular. Starting doses remain low, with glipizide beginning at 2.5-5mg daily and gliclazide at 40-80mg daily.
DPP-4 inhibitors, including sitagliptin and linagliptin, enhance the body’s incretin system, increasing insulin secretion when blood glucose rises while suppressing glucagon secretion. These medications rarely cause hypoglycemia when used alone and require no dose adjustment for meal timing.
SGLT2 inhibitors, such as empagliflozin and dapagliflozin, act in the kidneys to promote urinary glucose excretion. Beyond glucose control, these medications provide protection against cardiovascular and renal complications. Genital yeast infections represent the most common side effect, particularly in women.
Injectable Medications Beyond Insulin
GLP-1 receptor agonists mimic natural incretin hormones, enhancing insulin secretion while suppressing glucagon and slowing gastric emptying. Weekly formulations such as dulaglutide and semaglutide provide convenience while maintaining consistent glycemic control.
These medications promote weight loss, averaging 3-5kg over 6 months. Starting with lower doses minimises nausea, the primary side effect. Semaglutide is initiated at 0.25mg weekly for 4 weeks, then increased to 0.5mg, with potential further increases to 1mg or 2mg based on response.
💡 Did You Know?
GLP-1 receptor agonists work through multiple mechanisms: they enhance insulin release only when glucose levels rise, suppress inappropriate glucagon secretion, slow stomach emptying to reduce post-meal glucose spikes, and signal satiety in the brain.
Combining GLP-1 agonists with basal insulin provides comprehensive coverage. These fixed-ratio combinations simplify treatment for patients requiring both medications while reducing injection burden.
Insulin Therapy Options
Insulin therapy becomes necessary when oral medications cannot maintain glycemic targets or during periods of severe hyperglycemia. Basal insulin, like glargine or degludec, provides steady background insulin over 24 hours, typically starting at 10 units or 0.1-0.2 units/kg body weight at bedtime.
Basal insulin titration follows a systematic adjustment: increase by 2 units every 3 days if fasting glucose exceeds 7.0 mmol/L, continuing until the target is reached. Self-monitoring of blood glucose guides these adjustments.
Prandial (mealtime) insulin is used to manage postprandial hyperglycemia. Rapid-acting analogues such as aspart or lispro begin to work within 15 minutes, peaking at 1-2 hours. Starting doses are typically calculated as 4 units or 10% of the basal dose before the largest meal.
Premixed insulin combines intermediate-acting with rapid-acting insulin in fixed ratios (70/30 or 75/25). While convenient, premixed insulin offers less flexibility for varying meal sizes or timing. Twice-daily dosing before breakfast and dinner provides coverage for most patients.
⚠️ Important Note
Insulin storage requires careful attention: unopened vials or pens remain stable in the refrigerator until expiration date. Once opened, insulin can stay at room temperature (below 30°C) for 28 days. Never freeze insulin or expose it to direct sunlight.
Combination Therapy Strategies
Most patients eventually require multiple medications as beta-cell function declines. Combination therapy targets distinct mechanisms: metformin reduces hepatic glucose production, whereas DPP-4 inhibitors enhance insulin secretion, producing complementary effects.
Triple therapy adds a third mechanism when dual therapy proves insufficient. Common combinations include metformin with a sulfonylurea and SGLT2 inhibitor, or metformin with a DPP-4 inhibitor and basal insulin. Each addition targets glycemic control from a different angle.
The choice between adding oral agents versus insulin depends on current HbA1c levels, individual preferences, and cost considerations. HbA1c above 9.0% often necessitates insulin therapy for rapid glucose control, whereas levels between 7.5% and 9.0% may respond to oral combination therapy.
Sequential addition allows assessment of each medication’s contribution while minimising side effects. Allow 3 months between medication changes to evaluate the full glycemic impact through HbA1c testing.
Blood Glucose Monitoring Strategies
Self-monitoring frequency depends on treatment regimen and glycemic stability. Patients on basal insulin require daily fasting glucose checks, whereas those on intensive insulin therapy require 4-7 checks daily, including before meals and at bedtime.
Continuous glucose monitoring (CGM) systems provide glucose readings at 5-minute intervals via a subcutaneous sensor. CGM reveals glucose patterns that are not detectable with fingerstick monitoring, including overnight trends and postprandial excursions.
Time in range (TIR) is the percentage of time during which glucose remains between 3.9 and 10.0 mmol/L. Target TIR exceeds 70% for most adults with diabetes. CGM data identify periods requiring treatment adjustment.
Pattern management involves analysing glucose trends rather than reacting to individual readings. Three consecutive days of similar patterns at the same time indicate a need for treatment modification rather than temporary factors.
Managing Treatment Side Effects
Hypoglycemia remains the most serious acute complication, defined as blood glucose below 3.9 mmol/L. Symptoms include sweating, trembling, confusion, and hunger. Treatment requires 15 grams of rapid-acting carbohydrates, such as glucose tablets or regular soft drinks.
Gastrointestinal effects from metformin or GLP-1 agonists typically improve within 2-4 weeks. Taking medications with meals, starting with low doses, and gradually titrating can minimise these effects. Persistent symptoms may require a change in medication.
Weight gain associated with insulin or sulfonylureas averages 2-4kg in the first year. Combining with metformin or SGLT2 inhibitors helps mitigate weight gain. Careful insulin titration, avoiding overtreatment of mild hyperglycemia, prevents unnecessary weight gain.
✅ Quick Tip
Create a “sick day” medication plan with your doctor. During illness, blood glucose often rises even with reduced food intake. Having predetermined insulin dose adjustments or additional medication doses prevents severe hyperglycemia during illness.
Putting This Into Practice
- Test blood glucose at consistent times daily, recording results in a logbook or app along with food intake and medication timing to identify patterns requiring adjustment
- Prepare a hypoglycemia kit containing glucose tablets, a glucagon emergency kit, and medical identification, keeping supplies in multiple locations, including home, work, and vehicle
- Schedule medication refills when you have 2 weeks supply remaining, maintaining a buffer stock to prevent treatment interruptions during holidays or emergencies
- Rotate insulin injection sites systematically using different areas of the abdomen, thighs, and upper arms, staying 2-3cm away from the previous site to prevent lipodystrophy
- Review all medications with your healthcare provider every 3-6 months, discussing effectiveness, side effects, and potential simplification of complex regimens
When to Seek Professional Help
- Blood glucose consistently above 15 mmol/L despite taking prescribed medications
- Experiencing hypoglycemia more than twice weekly
- Unexplained weight loss exceeding 5kg over 2-3 months
- Persistent nausea or vomiting is preventing medication intake
- Signs of infection, including fever with glucose levels above the usual range
- Vision changes affecting the ability to read a glucose meter or draw insulin
- Numbness or tingling in the feet progressing up the legs
- Chest pain or shortness of breath with minimal exertion
- Non-healing wounds or cuts on the feet lasting more than one week
Commonly Asked Questions
How long does it take for diabetes medications to show full effect?
Metformin reaches maximal effectiveness within 2 weeks, whereas sulfonylureas are effective within days. DPP-4 inhibitors show full effect by 2-4 weeks. GLP-1 agonists require 4-5 weeks at each dose level, whereas SGLT2 inhibitors demonstrate maximal glucose-lowering effects within 1-2 weeks. HbA1c changes reflect average glucose over 3 months.
Can type 2 diabetes treatments be stopped if blood glucose normalises?
Type 2 diabetes treatments manage but don’t cure the condition. Stopping medications typically causes blood glucose to rise within days to weeks. Some patients who achieve significant weight loss may reduce medication doses under medical supervision, but complete discontinuation is rarely associated with long-term maintenance of normal glucose levels.
Why do some medications stop working over time?
Progressive beta-cell decline reduces insulin production capacity over time. This natural progression means treatments that stimulate insulin release become less effective. Additionally, weight gain, reduced physical activity, or other medications can worsen insulin resistance, requiring treatment intensification.
Should insulin be started immediately if diagnosed with very high blood glucose?
HbA1c above 10% or symptoms like excessive thirst, frequent urination, and weight loss indicate the need for immediate insulin therapy. Once glucose toxicity resolves (usually within 2-4 weeks), some patients can transition to oral medications. This “rescue” therapy preserves residual beta-cell function.
How do newer medications compare in protecting against complications?
SGLT2 inhibitors and GLP-1 agonists demonstrate cardiovascular benefits beyond glucose control, reducing heart attack and stroke risk. SGLT2 inhibitors, in particular, protect kidney function and slow the progression of diabetic kidney disease. These benefits influence medication choice beyond glycemic considerations.
Next Steps
Work with your healthcare team to find the combination that achieves your glycemic targets while minimising side effects and treatment burden.
If you’re experiencing challenges with current type 2 diabetes treatments or need a comprehensive evaluation of your management plan, our endocrinologist can assess your condition and optimise your treatment approach.
Disclaimer: Weight loss injections are prescription-only medications and may not be suitable for everyone. Please consult our doctor to determine your suitability and learn more about safe treatment options.
